CMC Biologics signs definitive agreement with AGC Asahi Glass.
International Resource News-December 20, 2016--CMC Biologics signs definitive agreement with AGC Asahi Glass
(C)1994-2016 ENPublishing - http://www.enpublishing.co.uk
International Resource News - 20 December 2016
(c)2005 - Electronic News Publishing - http://www.enpublishing.co.uk
CMC Biologics, a company involved in clinical and commercial manufacturing of monoclonal antibodies, coagulation factors and other therapeutic proteins, has signed a definitive agreement with AGC Asahi Glass, a manufacturer of glass, chemicals and high-tech materials.
The contract has been signed with CMC Biologics' shareholders including Monitor Clipper Partners, European Equity Partners and Innoven Partenaires, by which AGC will acquire 100 percent of CMC Biologics' shares. The deal is likely to be completed in January 2017.
David Kauffmann, chairman of CMC Biologics, said, 'With the high level of growth and success that CMC Biologics has had over the last 15 years, I am thrilled that we now will be a central part of AGC's pharmaceutical services business, with biologic manufacturing operations in Europe, U.S.A., and Asia. AGC is a world-class company dedicated to excellence and high customer satisfaction. AGC's commitment to best technology solutions and long-time partnership with clients align so well with CMC Biologics' mission to be the preferred biologics CDMO service partner for the world's top pharmaceutical and biotech companies.'
[Editorial queries for this story should be sent to firstname.lastname@example.org]
((Distributed via M2 Communications - http://www.m2.com))
|Printer friendly Cite/link Email Feedback|
|Publication:||International Resource News (IRN)|
|Date:||Dec 20, 2016|
|Previous Article:||Great Panther Silver signs contract with Nyrstar NV subsidiaries.|
|Next Article:||Vermilion Energy completes acquisition of interests in production and exploration assets in Germany from Engie E&P.|